Impressions on Safety Data from EMERALD Subgroup Analysis


Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.

Related Videos
Video 11 - "Treating Patients With RCC Who Progress Following Adjuvant Therapy"
Video 10 - "RCC: Informing Treatment Decisions with Clinical Trial Data"
Video 9 - "KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma"
Related Content